VAPO - Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids | Benzinga
Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention in children with acute severe asthma — a feasibility randomized controlled trial."
The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England.
Children who ...